Faron Pharma CEO talks about MHRA fast-track and phase III plans – ICYMI
Faron Pharmaceuticals Limited (AIM:LON:) CEO, Dr Juho Jalkanen, talked with Proactive about the significant fast-track designation awarded to their cancer immunotherapy, bexmarilimab, by the UK's MHRA. The drug is being used to treat people with relapsed refractory Myelodysplastic Syndrome (r/r...